Loading [Contrib]/a11y/accessibility-menu.js

This website uses cookies

We use cookies to enhance your experience and support COUNTER Metrics for transparent reporting of readership statistics. Cookie data is not sold to third parties or used for marketing purposes.

Skip to main content
University of San Francisco Law Review
  • Menu
  • Articles
    • General
    • All
  • For Authors
  • Editorial Board
  • About
  • Issues
  • Blog
  • search
  • LinkedIn (opens in a new tab)
  • RSS feed (opens a modal with a link to feed)

RSS Feed

Enter the URL below into your favorite RSS reader.

http://localhost:39619/feed
ISSN 0042-0018
General
Vol. 39, Issue 1, 2004January 01, 2004 PDT

The Superiority of Direct Proof of Monopoly Power and Anticompetitive Effects in Antitrust Cases Involving Delayed Entry of Generic Drugs

Eric L. Cramer, Daniel Berger,
AntitrustGeneric DrugsMonopolyAnticompetitiveHatch-WaxmanIntellectual PropertyDelayed Generic EntryPharmaceutical Industry
University of San Francisco Law Review
Eric L. Cramer & Daniel Berger, The Superiority of Direct Proof of Monopoly Power and Anticompetitive Effects in Antitrust Cases Involving Delayed Entry of Generic Drugs, 39 University of San Francisco Law Review 4 (2004).

View more stats

Powered by Scholastica, the modern academic journal management system